Small-molecule API CDMOs in Europe: 107 compared (2026)
107 of the 255 contract development and manufacturing organisations in A4BEE’s European census list small-molecule API manufacturing among their capabilities. The largest, with revenue over €1bn, are ACS Dobfar, Almac Group, Biovet (Huvepharma), ESTEVE (Química / CDMO), F.I.S. Fabbrica Italiana Sintetici, Fareva and 11 more. 44 sit between €250m and €1bn and 46 are smaller or niche.
By ownership: 35 family-owned, 24 private equity, 18 listed, 27 part of a pharma or industrial group and 3 state-owned. They are spread across 27 countries, led by Italy (18), Spain (17), the United Kingdom (12), Switzerland (9) and Germany (8). 65 of the 107 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.
107 companies
Small-molecule API CDMOs in Europe
| Company | Country | Ownership | Size | Revenue (as reported) | Modalities | Data |
|---|---|---|---|---|---|---|
| ACS DobfarItalian anti-infectives specialist (1973). Vertically integrated: cephalosporin/carbapenem/penicillin APIs AND finished dosage on a CDMO basis. | Tribiano, Italy | Family-owned | Tier 1 | not disclosed | Small-molecule API, Sterile fill-finish, Oral solid dose | high |
| Almac Group£400 m+ capex program; broad clinical + diagnostics services alongside API. | Craigavon, United Kingdom | Family-ownedMcClay charitable trust | Tier 1 | £1.027 bn FY2024 | Small-molecule API, Peptide, Antibody-drug conjugate (ADC) | high |
| Biovet (Huvepharma)Huge fermentation platform — mainly own animal-health APIs but offers custom synthesis/fermentation and human-health APIs. CDMO relevance is microbial API. | Peshtera, Bulgaria | Family-ownedHuvepharma / Domuschiev family | Tier 1 | not disclosed | Microbial and protein, Small-molecule API | low |
| ESTEVE (Química / CDMO)Self-described 'Champion Small-Molecule CDMO'; APIs, HPAPIs and advanced intermediates for third parties. | Barcelona, Spain | Family-ownedEsteve family | Tier 1 | not disclosed | Small-molecule API | high |
| F.I.S. Fabbrica Italiana SinteticiOne of the largest small-molecule API CDMOs in the world. Strong GLP-1 growth. Controlled by Bain Capital since 2023. | Montecchio Maggiore, Italy | Private equityBain Capital | Tier 1 | €879 m (2025) | Small-molecule API | high |
| Fareva | Luxembourg, Luxembourg | Family-owned | Tier 1 | ~€2.2 bn | Sterile fill-finish, Oral solid dose, Small-molecule API, Monoclonal antibody | medium |
| Gedeon RichterPrimarily own-product/biosimilar pharma, but runs a real biologics CDMO arm (mammalian DS + fill-finish) and microbial CDMO via Richter-Helm. Group figures mostly non-CDMO. | Budapest, Hungary | Listed | Tier 1 | ~€2.1 bn (2023, group) | Biologics and biosimilars, Monoclonal antibody, Microbial and protein, Sterile fill-finish, Small-molecule API | high |
| HovioneFully integrated specialist CDMO: API, particle engineering/spray drying, drug product. FDA-inspected across 3 continents. | Loures, Portugal | Family-ownedVillax family | Tier 1 | not disclosed | Small-molecule API, Oral solid dose | high |
| Insud Pharma (Chemo)Group-level entity. Chemo industrial division provides CMO/CDMO across most dosage forms incl. injectables. Parent of Liconsa and León Farma. | Madrid, Spain | Family-ownedGrupo Insud | Tier 1 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish, Biologics and biosimilars, Monoclonal antibody | high |
| LonzaIntegrated Biologics grew +32.2% CER in 2025; the sector's clear scale + digital leader. | Basel, Switzerland | Listed | Tier 1 | CHF 6.5 bn (2025) | Biologics and biosimilars, Monoclonal antibody, Antibody-drug conjugate (ADC), Small-molecule API, Cell and gene therapy, Microbial and protein | high |
| OlonOne of Europe's largest API CDMOs; absorbed Euticals. Chemical synthesis + microbial fermentation, HPAPI, ADC bioconjugation. | Rodano, Italy | Family-owned | Tier 1 | ~€546 m (2024, group) | Small-molecule API, Microbial and protein, Peptide, Antibody-drug conjugate (ADC), Biologics and biosimilars | high |
| Patheon ItaliaItaly CDMO sites of Thermo Fisher (Patheon). Sterile/lyo + high-potency + mRNA/LNP. | Ferentino, Italy | Part of a pharma or industrial groupThermo Fisher Scientific | Tier 1 | not disclosed | Sterile fill-finish, Biologics and biosimilars, mRNA and LNP, Small-molecule API | low |
| Rovi Pharma Industrial ServicesBest-known Spanish injectables fill-finish CDMO; performed fill-finish of the Moderna COVID vaccine. Rebranded 'Rois' (2024). | Madrid, Spain | ListedLaboratorios ROVI | Tier 1 | Group ROVI ~€1.0 bn | Sterile fill-finish, Oral solid dose, Small-molecule API | high |
| SeqensLarge API/small-molecule CDMO plus specialty ingredients; ~200 APIs. Revenue includes non-pharma specialty ingredients. | Écully, France | Private equitySK Capital | Tier 1 | ~€1.1 bn (group) | Small-molecule API, Peptide | high |
| Siegfried | Zofingen, Switzerland | Listed | Tier 1 | CHF 1.29 bn (2024) | Small-molecule API, Sterile fill-finish | low |
| SopharmaListed Bulgarian pharma with a dedicated CDMO business unit: sterile/non-sterile liquids, oral solids/semi-solids, API, packaging/serialization; handles controlled substances. | Sofia, Bulgaria | Listed | Tier 1 | not disclosed | Oral solid dose, Sterile fill-finish, Small-molecule API | high |
| Zentiva GroupLarge generics maker with an explicit B2B/CDMO arm (oral solids, sterile ampoules/vials, creams; APIs). Contract offering spans Prague and Bucharest. | Prague, Czechia | Private equityAdvent International | Tier 1 | ~€1.3 bn (group est.) | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| Adamed Pharma | Pieńków, Poland | Family-owned | Tier 2 | >PLN 1.6 bn (2023) | Small-molecule API, Oral solid dose | medium |
| Adragos PharmaFSN Capital 'buy-and-build' roll-up acquiring sites from Sanofi/Fresenius Kabi. | Munich, Germany | Private equityFSN Capital | Tier 2 | n/d | Small-molecule API, Sterile fill-finish, Oral solid dose | medium |
| Ajinomoto Bio-Pharma (OmniChem)Small-molecule API CDMO: HPAPIs, ADC conjugation, oligonucleotides, continuous-flow chemistry. | Wetteren, Belgium | Part of a pharma or industrial groupAjinomoto | Tier 2 | not disclosed | Small-molecule API, Peptide, Antibody-drug conjugate (ADC) | high |
| Antibiotice IașiState-controlled, BVB-listed; world leader in Nystatin API by fermentation. Explicit EU-GMP contract manufacturing plus sterile injectables, capsules, tablets. | Iași, Romania | State-ownedRomanian state (majority) | Tier 2 | not disclosed | Small-molecule API, Microbial and protein, Oral solid dose, Sterile fill-finish | high |
| APL (Apotek Produktion & Laboratorier)State-owned; dual mandate of extemporaneous compounding for Sweden plus a commercial CDMO arm. | Stockholm, Sweden | State-ownedSwedish State | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish, Small-molecule API | high |
| Aptuit (Evotec)Integrated CMC CDMO of Evotec (Aptuit acquired 2017). GMP API drug substance + drug-product to commercial scale. | Verona, Italy | Part of a pharma or industrial groupEvotec | Tier 2 | not disclosed | Small-molecule API, Oral solid dose | medium |
| AxploraAPI/HPAPI specialist across German and French sites. | Munich, Germany | Private equity | Tier 2 | n/d | Small-molecule API, Antibody-drug conjugate (ADC) | low |
| BachemSIX-listed peptide & oligonucleotide CDMO; largest independent peptide maker. | Bubendorf, Switzerland | Listed | Tier 2 | CHF 605.3 m (2024) | Peptide, Small-molecule API | high |
| BioSpringPrivately held German nucleic-acid CDMO (oligonucleotides — ASO, siRNA, guide RNA — plus mRNA). Fills a modality gap the roster otherwise lacks. | Frankfurt am Main, Germany | Family-owned | Tier 2 | not disclosed | mRNA and LNP, Small-molecule API | medium |
| CambrexSmall-molecule API + continuous flow + liquid-phase peptides; several EU sites. | East Rutherford, NJ, United States | Private equityPermira | Tier 2 | ~US$500 m–1 bn | Small-molecule API, Peptide | medium |
| Cambrex Profarmaco MilanoItalian operating entity of US-HQ Cambrex; generic APIs + custom/contract manufacturing of APIs and intermediates. | Paullo, Italy | Private equityCambrex (Permira) | Tier 2 | not disclosed | Small-molecule API | medium |
| Centrient PharmaceuticalsFormerly DSM Sinochem. Enzymatic beta-lactam antibiotics, statins, antifungals; APIs plus finished dosage and CDMO. | Rijswijk, Netherlands | Private equityBain Capital | Tier 2 | ~€560 m | Small-molecule API, Microbial and protein | high |
| ChemiCustom/contract API manufacturing plus complex generics and proprietary peptides, low-molecular-weight heparins. | Cinisello Balsamo, Italy | Part of a pharma or industrial groupItalfarmaco Group | Tier 2 | not disclosed | Small-molecule API, Peptide, Biologics and biosimilars | high |
| CIPANAPI CDMO via fermentation and chemical synthesis (founded 1960). FDA-approved; anti-infectives, psychotropics. Part of Suanfarma. | Castanheira do Ribatejo, Portugal | Private equitySuanfarma | Tier 2 | not disclosed | Small-molecule API, Microbial and protein | high |
| CordenPharmaPeptide + lipid/LNP specialist riding the GLP-1 boom (e.g. Viking deal). | Basel, Switzerland | Private equity | Tier 2 | ~US$530 m | Peptide, mRNA and LNP, Sterile fill-finish, Small-molecule API | medium |
| DEMOPrimarily own-product (largest injectables supplier to Greek hospitals) but lists contract manufacturing. Own-API from 2019. | Krioneri, Greece | Family-owned | Tier 2 | not disclosed | Sterile fill-finish, Small-molecule API | medium |
| Dipharma FrancisGlobal CDMO + generic API manufacturer (>40 APIs) plus exclusive/custom synthesis. FDA-inspected. | Baranzate, Italy | Family-owned | Tier 2 | not disclosed | Small-molecule API | medium |
| Dottikon ES HoldingSIX-listed exclusive-synthesis CDMO specialising in hazardous chemistry, APIs, HPAPIs and intermediates. | Dottikon, Switzerland | Listed | Tier 2 | CHF 424.3 m (H1 FY25/26) | Small-molecule API | high |
| EthypharmHybrid specialty pharma + CDMO; CDMO arm specializes in controlled substances, HPAPIs and modified-release oral. | Saint-Cloud, France | Private equityPAI Partners | Tier 2 | €135 m (2024, SAS) | Oral solid dose, Small-molecule API | medium |
| EUROAPIEuronext Paris; Sanofi ~30% + Bpifrance. ~200 small-molecule APIs plus peptides and oligos. | Paris, France | Listed | Tier 2 | €911.9 m (2024), −10% | Small-molecule API, Peptide | low |
| Evonik Health CareDrug-substance CDMO for complex APIs, HPAPIs and pharmaceutical lipids (LNP/RNA delivery). | Essen, Germany | ListedEvonik Industries | Tier 2 | not disclosed | Small-molecule API, Peptide | low |
| FarmabiosWorld leader in steroid chemistry (>80 APIs) + CDMO for HPAPIs, cytotoxics, hormones. Italian site of Axplora group. | Gropello Cairoli, Italy | Private equityAxplora | Tier 2 | not disclosed | Small-molecule API | high |
| Farmhispania GroupIndependent private API CDMO; leading European CDMO in HPAPI (cytotoxics) plus fermentation and large-scale lyophilisation. | Montmeló, Spain | Family-owned | Tier 2 | not disclosed | Small-molecule API, Microbial and protein | high |
| FermionOrion's dedicated CDMO arm; small-molecule API CDMO (Phase I→commercial) incl. HPAPI/cytotoxic. Two FDA/EMA-approved API sites. | Espoo, Finland | Part of a pharma or industrial groupOrion Corporation | Tier 2 | not disclosed | Small-molecule API, Oral solid dose | high |
| FlammaFamily-owned small-molecule API CDMO since 1950; leader in amino acids and peptide building blocks. FDA-inspected. | Chignolo d'Isola, Italy | Family-ownedNegrisoli family | Tier 2 | not disclosed | Small-molecule API, Peptide | high |
| Fresenius Kabi Contract Manufacturing'Product Partnering' contract-manufacturing platform for sterile injectables, emulsions, liposomes and biologics. | Bad Homburg, Germany | ListedFresenius | Tier 2 | not disclosed | Sterile fill-finish, Biologics and biosimilars, Small-molecule API | medium |
| GrindeksMajor Baltic pharma that formally launched CDMO services (2025): API dev/manufacturing incl. HPAPIs, plus solid/liquid/semi-solid FDFs. Sterile injectables via Kalceks. | Riga, Latvia | Family-ownedKirovs Lipmans (majority) | Tier 2 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| ICE (Industria Chimica Emiliana)World-leading integrated producer of bile-acid APIs (UDCA, TUDCA); custom-CDMO role narrower. Founded 1949. | Reggio Emilia, Italy | Family-owned | Tier 2 | not disclosed | Small-molecule API | medium |
| Interquim (Ferrer)API arm of Spanish pharma group Ferrer; develops/manufactures APIs with custom synthesis and contract manufacturing. | Sant Cugat del Vallès, Spain | Part of a pharma or industrial groupFerrer | Tier 2 | not disclosed | Small-molecule API | high |
| Kern PharmaDedicated 'Production to Third Parties' line. 3rd-largest Spanish generics producer by volume; chemical plant synthesises APIs. | Terrassa, Spain | Family-ownedGrupo Indukern | Tier 2 | not disclosed | Oral solid dose, Small-molecule API | high |
| Laboratorios NormonPrimarily own-product generics leader; offers CMO services via its International Division. CMO is a secondary line. | Tres Cantos, Spain | Family-owned | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish, Small-molecule API | medium |
| MinakemAPI and HPAPI CDMO (custom synthesis). Brand of the privately-held Minafin Group. | Dunkerque, France | Family-ownedMinafin Group | Tier 2 | not disclosed | Small-molecule API | medium |
| Moehs GroupIndustrial holding producing APIs + CDMO/custom-manufacturing; >75 products, >80 DMFs. Founded 1962. | Rubí, Spain | Part of a pharma or industrial groupPMC Global (US) | Tier 2 | ~€40 m/yr (Moehs Ibérica) | Small-molecule API | high |
| Novo Nordisk PharmatechThird-party supplier of quaternary ammonium APIs/excipients, recombinant insulin for media, and recombinant enzymes. Sells to external customers. | Køge, Denmark | Part of a pharma or industrial groupNovo Nordisk | Tier 2 | not disclosed | Small-molecule API, Microbial and protein, Biologics and biosimilars | high |
| Olainfarm (Olpha)One of the largest Baltic pharma companies (rebranded Olpha); contract manufacturing and co-development across APIs, intermediates and solid FDFs. | Olaine, Latvia | Private equityAB City holding | Tier 2 | not disclosed | Small-molecule API, Oral solid dose | high |
| PROCOSCustom synthesis (~70% of turnover) + generic APIs; active in HPAPI and ADC drug-linkers. Owned by Japan's CBC. | Cameri, Italy | Part of a pharma or industrial groupCBC Group (Japan) | Tier 2 | €233.8 m (2024) | Small-molecule API, Antibody-drug conjugate (ADC) | high |
| Quotient SciencesFull-service third-party CDMO (drug substance/product + clinical). UK-HQ under European PE. | Nottingham, United Kingdom | Private equityPermira | Tier 2 | not disclosed | Small-molecule API, Oral solid dose, Peptide, Sterile fill-finish | low |
| Reig JofreMarket leader in complex generics; CDMO covers sterile/lyophilized injectables plus beta-lactam antibiotics in segregated facilities. | Sant Joan Despí, Spain | Listed | Tier 2 | €339 m (2024) | Sterile fill-finish, Small-molecule API, Oral solid dose | high |
| SaltigoLanxess custom-manufacturing subsidiary producing APIs, complex intermediates and RSMs at multi-ton scale. | Leverkusen, Germany | Part of a pharma or industrial groupLanxess | Tier 2 | not disclosed | Small-molecule API | high |
| Saneca PharmaceuticalsSlovakia's largest pharma and a genuine API + FDF CDMO (carve-out of former Zentiva/Sanofi API business). Opiate/narcotic API specialist plus oral solids. | Hlohovec, Slovakia | Private equity | Tier 2 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| SUANFARMASpain-HQ B2B life-sciences; CDMO offers end-to-end small-molecule dev/manufacturing combining fermentation and synthesis. | Alcobendas, Spain | Private equityArchiMed | Tier 2 | not disclosed | Small-molecule API, Microbial and protein | high |
| TAPI CroatiaTeva's API arm operates the Savski Marof site with a rare sterile-API facility explicitly offering third-party CDMO services. | Savski Marof, Croatia | Part of a pharma or industrial groupTeva | Tier 2 | not disclosed | Small-molecule API, Sterile fill-finish | high |
| UQUIFAAPI manufacturer with explicit CDMO franchise (off-patent APIs + custom development). ~85 yrs history. | Barcelona, Spain | Part of a pharma or industrial groupVivimed Labs (India) | Tier 2 | not disclosed | Small-molecule API | high |
| Xellia PharmaceuticalsFermentation-based non-beta-lactam anti-infectives; APIs + FDF to 500+ pharma companies, plus CMO/CDMO services. Phasing out Copenhagen manufacturing. | Copenhagen, Denmark | Part of a pharma or industrial groupNovo Holdings | Tier 2 | not disclosed | Small-molecule API, Sterile fill-finish, Microbial and protein | high |
| APC / VLE TherapeuticsIrish-founded (UCD spinout). APC = process-dev/CMC; sister VLE runs the GMP 'factory of the future' — the group has genuine manufacturing. | Dublin, Ireland | Family-owned | Tier 3 | not disclosed | Small-molecule API, Biologics and biosimilars, Viral vector and vaccine, mRNA and LNP | high |
| Aspen OssBiochemical/chemical API CDMO: steroid hormones, heparin, peptides, alkaloids. Former Organon/Merck site. | Oss, Netherlands | ListedAspen Pharmacare | Tier 3 | not disclosed | Small-molecule API, Peptide | high |
| AxolabsOligonucleotide and nucleic-acid CRO/CDMO, part of LGC. Berlin cGMP oligo manufacturing. | Kulmbach, Germany | Part of a pharma or industrial groupLGC | Tier 3 | not disclosed | Small-molecule API, mRNA and LNP | medium |
| BDD PharmaSmall CDMO/CRO for modified/controlled-release oral formulation dev (proprietary OralogiK). More formulation-dev than commercial scale. | Glasgow, United Kingdom | Private equity | Tier 3 | not disclosed | Small-molecule API, Oral solid dose | low |
| BimedaIrish family-owned global animal-health company; contract/private-label veterinary manufacturing (drenches, nutritional liquids, ecto-parasiticides). | Dublin, Ireland | Family-owned | Tier 3 | not disclosed | Small-molecule API, Sterile fill-finish, Oral solid dose | medium |
| Bioindustria L.I.M.Own + third-party manufacturing. Sterile injectable/freeze-dried solutions and non-sterile tablets/capsules; also an API dept. | Novi Ligure, Italy | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Small-molecule API | high |
| CARBOGEN AMCISDrug-substance & drug-product CDMO (incl. HPAPI/ADC); Swiss arm of Indian-listed Dishman Carbogen Amcis. | Bubendorf, Switzerland | Part of a pharma or industrial groupDishman Carbogen Amcis (India) | Tier 3 | not disclosed | Small-molecule API, Antibody-drug conjugate (ADC) | medium |
| CatSciContract development organisation (route scouting, API/HPAPI process dev, analytical) — the 'D' of CDMO; outsources scale-up. | Cardiff, United Kingdom | Private equityKeensight Capital | Tier 3 | not disclosed | Small-molecule API | low |
| Celon Pharma | Łomianki, Poland | Listed | Tier 3 | PLN 207 m (2024) | Small-molecule API, mRNA and LNP, Biologics and biosimilars | high |
| Cerbios-Pharma~50-year-old CDMO for HPAPIs, ADCs, recombinant proteins and live biotherapeutics; acquired by HAS Healthcare 2025. | Lugano, Switzerland | Private equityHAS Healthcare | Tier 3 | not disclosed | Small-molecule API, Antibody-drug conjugate (ADC), Biologics and biosimilars, Microbial and protein | high |
| Chanelle PharmaIreland's largest indigenous generics maker (human + veterinary); explicitly offers CMO/CDMO services alongside own generics. | Loughrea, Ireland | Private equityExponent Private Equity | Tier 3 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| ChemConcGMP API / fine-chemical CDMO with high-containment HPAPI/cytotoxic capability; FDA-inspected. | Freiburg, Germany | Family-owned | Tier 3 | not disclosed | Small-molecule API | medium |
| Combino PharmGenerics developer that licenses out dossiers and offers third-party contract manufacturing, mainly via its Malta plant. | Sant Joan Despí, Spain | Family-ownedCorporación Medichem | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Small-molecule API | medium |
| CovexIndependent Spanish API maker since 1977; specialist in vinca alkaloids. CMO/CDMO for third-party API manufacturing. | Colmenar Viejo, Spain | Family-owned | Tier 3 | not disclosed | Small-molecule API | high |
| Custom Pharma ServicesFull-service oral-solid-dose CDMO (tablets/capsules/powders incl. HPAPI); process dev through commercial. Est. 1979. | Hove, United Kingdom | Family-owned | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | high |
| DeretilGlobal leader in side chains for beta-lactam antibiotics; custom synthesis/enzymatic chiral tech. Founded 1961. | Cuevas del Almanzora, Spain | Family-owned | Tier 3 | not disclosed | Small-molecule API, Microbial and protein | high |
| EirGen PharmaIrish-HQ specialist HPAPI/oncology OSD CDMO (cytotoxic, genotoxic, steroidal) for external clients. Owned by OPKO (US). | Waterford, Ireland | Part of a pharma or industrial groupOPKO Health (US) | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | high |
| Ercros (Pharmaceuticals)Listed chemicals group; pharma division makes generic APIs (antibiotics via fermentation) AND custom/contract manufacturing. | Aranjuez, Spain | Listed | Tier 3 | not disclosed | Small-molecule API, Microbial and protein | high |
| ErregierreFamily company (1974) making small/medium-volume APIs (human + veterinary); contract manufacturing + DMF/CEP support. | San Paolo d'Argon, Italy | Family-ownedGargani family | Tier 3 | not disclosed | Small-molecule API | high |
| GalenicaPrivately owned Swedish CDMO (est. 1999); dev + GMP manufacture of solids, liquids, semi-solids, small molecules and peptides incl. high-potency. | Malmö, Sweden | Family-owned | Tier 3 | not disclosed | Oral solid dose, Peptide, Small-molecule API | high |
| HAS Healthcare Advanced SynthesisEx-Helsinn HPAPI/anticancer API CDMO spun out as independent in 2022; now parent of Cerbios. | Biasca, Switzerland | Family-ownedBraglia family | Tier 3 | not disclosed | Small-molecule API, Antibody-drug conjugate (ADC) | high |
| Helsinn Birex PharmaceuticalsIrish-registered entity primarily making the Swiss parent's products; advertises third-party OSD + gel/cream contract manufacturing. Closer to captive site. | Dublin, Ireland | Part of a pharma or industrial groupHelsinn Group (Switzerland) | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish, Small-molecule API | low |
| IdifarmaNiche small-molecule CDMO specialising in HPAPI/oncology small-batch manufacturing and spray-drying. | Pamplona, Spain | Part of a pharma or industrial groupArdena | Tier 3 | not disclosed | Small-molecule API, Oral solid dose | high |
| Lamp San ProsperoItalian oral-solid-dose CDMO. Non-biologics tier-3 addition for completeness. | San Prospero, Italy | Family-owned | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | medium |
| Magle ChemoswedVertically-integrated CDMO/CMO for pharma and med-tech: intermediates → APIs, niche formulation, fill-finish, QP release. FDA-inspected. | Malmö, Sweden | Listed | Tier 3 | not disclosed | Small-molecule API, Sterile fill-finish | high |
| Micro-SphereFounder-led CDMO specialising in spray drying (poorly-soluble drugs) and capsule filling, clinical to commercial. | Monteggio, Switzerland | Family-owned | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | high |
| NanoformNanoparticle drug-particle-engineering CDMO (CESS nanoforming for small molecules + a biologics platform); formulation, analytical + GMP API. Nasdaq First North. | Helsinki, Finland | Listed | Tier 3 | not disclosed | Small-molecule API, Biologics and biosimilars | high |
| NerPharMaHPAPI/oncology CDMO offering integrated drug substance + drug product: injectables and oral solids. EMA + FDA accredited. | Nerviano, Italy | Part of a pharma or industrial groupBenta Group (Lebanon) | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, Small-molecule API | high |
| NewchemItalian API maker (1998) specializing in steroids, hormones, prostaglandins; custom synthesis + contract (~53 APIs). | Milan, Italy | Part of a pharma or industrial groupZhejiang Xianju (China) | Tier 3 | not disclosed | Small-molecule API | high |
| Onyx ScientificSmall-molecule API / process-R&D CDMO; GMP API early phase to commercial. Owned by Ipca (India). | Sunderland, United Kingdom | Part of a pharma or industrial groupIpca Laboratories (India) | Tier 3 | not disclosed | Small-molecule API | low |
| Palla Pharma NorwayNorwegian maker of opiate-based APIs and finished dose (est. 1949). Primarily a merchant/own-product opiate-API producer rather than a client-driven CDMO. | Kragerø, Norway | Family-owned | Tier 3 | not disclosed | Small-molecule API, Oral solid dose | low |
| Pharmaron Cramlington (formerly Aesica)Third-party commercial API CDMO HQ'd in Cramlington. Was Aesica (Recipharm); sold to Pharmaron 2022 and rebranded. | Cramlington, United Kingdom | Part of a pharma or industrial groupPharmaron (China) | Tier 3 | not disclosed | Small-molecule API | medium |
| PharmatoryFinnish CDMO: small-molecule synthesis, process R&D, cGMP API contract manufacturing and analytics for human and veterinary pharma. | Oulu, Finland | Private equityMB Funds | Tier 3 | not disclosed | Small-molecule API | high |
| PMC IsochemCustom API and peptide CDMO. Acquired by PMC Group (US) in 2017. | Vert-le-Petit, France | Part of a pharma or industrial groupPMC Group | Tier 3 | not disclosed | Small-molecule API, Peptide | high |
| Polfa TarchominState-owned; anti-infectives + insulin + ampoules/vials/lyo. | Warsaw, Poland | State-owned | Tier 3 | n/d | Small-molecule API, Biologics and biosimilars, Sterile fill-finish | medium |
| Porton PharmaTechEuropean subsidiary of China's Porton; billed as the first true CDMO in Slovenia — small-molecule API route dev, kilo-lab and GMP drug-substance. | Mengeš, Slovenia | Part of a pharma or industrial groupPorton Pharma Solutions (China) | Tier 3 | not disclosed | Small-molecule API | high |
| Quality ChemicalsIndependent Spanish CDMO (40+ yrs) specializing in inorganic/organic salts in API and excipient grades. GMP/ISO. | Esparreguera, Spain | Family-owned | Tier 3 | not disclosed | Small-molecule API | high |
| Quay Pharma (SGS)Formulation-development + clinical/commercial CDMO HQ'd in Deeside, Wales. Acquired by SGS (Switzerland). | Deeside, United Kingdom | Part of a pharma or industrial groupSGS | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | medium |
| Rosemont PharmaceuticalsOral-liquid-medicines specialist (~60 yrs); primarily branded/specials but offers contract manufacturing/CDMO services. | Leeds, United Kingdom | Private equityInflexion | Tier 3 | not disclosed | Small-molecule API, Oral solid dose | medium |
| Sanochemia PharmazeutikaCDMO for sterile injectables and small-molecule APIs; also a leading MRI/CT contrast-agent maker. | Neufeld an der Leitha, Austria | Private equityEOSS Industries consortium | Tier 3 | not disclosed | Small-molecule API, Sterile fill-finish | high |
| SelvitaCRO drug-discovery house with a growing CDMO/analytical arm (via the PozLab acquisition). | Kraków, Poland | Listed | Tier 3 | €80.4 m (2024) | Small-molecule API | high |
| Sterling Pharma | Cramlington, United Kingdom | Private equityGHO Capital | Tier 3 | ~£130 m FY2023 | Small-molecule API, Antibody-drug conjugate (ADC), Peptide | medium |
| Symbiosis Pharmaceutical ServicesIndependent sterile aseptic fill-finish CDMO (clinical + commercial): mAbs, ATMPs, viral vectors, ADCs, vaccines. FDA-inspected. | Stirling, United Kingdom | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Antibody-drug conjugate (ADC), Biologics and biosimilars, Cell and gene therapy, Small-molecule API | medium |
| Vistin PharmaEuronext Growth Oslo-listed metformin-HCl API producer (~10% of world demand). Primarily own-product merchant API maker with intent to become a multiproduct API CDMO. | Oslo, Norway | Listed | Tier 3 | not disclosed | Small-molecule API | low |
| Wockhardt UK (CP Pharmaceuticals)UK operating entity; third-party contract manufacture of sterile injectables (vials, cartridges, ampoules, lyo) alongside own generics. | Wrexham, United Kingdom | Part of a pharma or industrial groupWockhardt (India) | Tier 3 | not disclosed | Sterile fill-finish, Small-molecule API, Biologics and biosimilars | medium |
| Zach SystemFine-chemical/API arm of Italy's Zambon group; Italian API production divested to FIS, remaining manufacturing in France. | Bresso, Italy | Part of a pharma or industrial groupZambon | Tier 3 | not disclosed | Small-molecule API | medium |
Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).
Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.
Browse the census
Other European CDMO lists
By country
- CDMOs in Italy (31)
- CDMOs in Spain (30)
- CDMOs in Germany (28)
- CDMOs in the United Kingdom (25)
- CDMOs in France (15)
- CDMOs in Switzerland (14)
- CDMOs in Poland (11)
- CDMOs in Belgium (9)
- CDMOs in Sweden (9)
- CDMOs in Greece (8)
- CDMOs in Ireland (8)
- CDMOs in the Netherlands (8)
- CDMOs in Portugal (8)
- CDMOs in Denmark (7)
- CDMOs in Austria (5)
- CDMOs in Finland (5)
- CDMOs in Norway (5)
- CDMOs in Czechia (4)
- CDMOs in Lithuania (4)
- CDMOs in Bulgaria (3)
By modality
- Small-molecule API CDMOs in Europe
- Oral solid dose CDMOs in Europe (94)
- Sterile fill-finish CDMOs in Europe (106)
- Biologics and biosimilars CDMOs in Europe (66)
- Monoclonal antibody CDMOs in Europe (36)
- Antibody-drug conjugate (ADC) CDMOs in Europe (15)
- Cell and gene therapy CDMOs in Europe (29)
- mRNA and LNP CDMOs in Europe (22)
- Viral vector and vaccine CDMOs in Europe (32)
- Microbial and protein CDMOs in Europe (34)
- Peptide CDMOs in Europe (24)